Related Experiment Videos
[Tyrosine kinase: implications in tumor pathology and therapeutic perspectives]
F Peyrade1, B Taillan, C Lebrun
1Service d'hématologie-médecine interne, Hôpital de Cimiez, Nice, France.
Abstract:
The tyrosine kinase family includes growth factor receptor and cytoplasmic enzymes. It plays a key role in normal cell division and abnormal cell proliferation and differentiation. The most common tyrosine kinases are the epidermal-growth factor (EGFR) and platelet-derived growth factor (PDGF) receptors, and a chromosome Philadelphia product, the Bcr-abl oncogene. Many studies have attempted to correlate clinical evolution of tumors with tyrosine kinase expression. However, clinical application of these new prognostic factors has not yet been demonstrated. More recently, tyrosine-phosphorylation inhibitors (tryphostin) have been developed in phase I studies. Results that were obtained show some objective responses in patients with glioblastoma and polymetastatic cancer. Another approach to block tyrosine kinase expression is the use of monoclonal antibodies. Trials using such antibodies have shown interesting preliminary results.
Insights
Tyrosine kinases regulate cell division and growth. Inhibitors targeting these kinases show promise in treating cancers like glioblastoma, with early trials indicating objective responses.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Tyrosine kinases are crucial enzymes regulating cell division, proliferation, and differentiation.
- Dysregulation of tyrosine kinases is implicated in various cancers.
- Common examples include epidermal-growth factor (EGFR) and platelet-derived growth factor (PDGF) receptors, and the Bcr-abl oncogene.
Purpose of the Study:
- To review the role of tyrosine kinases in cancer.
- To discuss emerging therapeutic strategies targeting tyrosine kinases, including inhibitors and monoclonal antibodies.
Main Methods:
- Review of existing literature on tyrosine kinase function and expression in tumors.
- Analysis of preliminary clinical trial data for tyrosine-phosphorylation inhibitors (tryphostins) and monoclonal antibodies.
Main Results:
- Tyrosine kinase expression correlates with tumor progression, though clinical application as prognostic factors is still under investigation.
- Phase I trials of tryphostins demonstrated objective responses in patients with glioblastoma and polymetastatic cancer.
- Early trials of monoclonal antibodies targeting tyrosine kinases have yielded promising preliminary results.
Conclusions:
- Targeting tyrosine kinases represents a significant therapeutic avenue in oncology.
- Tyrosine-phosphorylation inhibitors and monoclonal antibodies show potential for treating various cancers, warranting further clinical investigation.